- Home
- CCD vs ANAB Comparison
CCD vs ANAB Comparison
Compare CCD & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCD
- ANAB
- Stock Information
- Founded
- CCD 2014
- ANAB 2005
- Country
- CCD United States
- ANAB United States
- Employees
- CCD N/A
- ANAB N/A
- Industry
- CCD Trusts Except Educational Religious and Charitable
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- CCD Finance
- ANAB Health Care
- Exchange
- CCD Nasdaq
- ANAB Nasdaq
- Market Cap
- CCD 543.5M
- ANAB 621.1M
- IPO Year
- CCD N/A
- ANAB 2017
- Fundamental
- Price
- CCD $19.42
- ANAB $23.17
- Analyst Decision
- CCD
- ANAB Buy
- Analyst Count
- CCD 0
- ANAB 10
- Target Price
- CCD N/A
- ANAB $44.25
- AVG Volume (30 Days)
- CCD 96.1K
- ANAB 775.6K
- Earning Date
- CCD 01-01-0001
- ANAB 08-04-2025
- Dividend Yield
- CCD 10.61%
- ANAB N/A
- EPS Growth
- CCD N/A
- ANAB N/A
- EPS
- CCD N/A
- ANAB N/A
- Revenue
- CCD N/A
- ANAB $111,872,000.00
- Revenue This Year
- CCD N/A
- ANAB N/A
- Revenue Next Year
- CCD N/A
- ANAB $24.39
- P/E Ratio
- CCD N/A
- ANAB N/A
- Revenue Growth
- CCD N/A
- ANAB 387.20
- 52 Week Low
- CCD $16.93
- ANAB $12.21
- 52 Week High
- CCD $24.68
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- CCD 22.62
- ANAB 56.01
- Support Level
- CCD $19.77
- ANAB $22.46
- Resistance Level
- CCD $20.38
- ANAB $24.17
- Average True Range (ATR)
- CCD 0.24
- ANAB 1.72
- MACD
- CCD -0.05
- ANAB -0.01
- Stochastic Oscillator
- CCD 17.65
- ANAB 73.23
About CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).